Health Care Stocks Still Healthy Despite Higher Hedging Costs

NEW YORK (TheStreet) -- Analysts predict earnings will soar by 11% for health care companies, higher than the 7.2% increase by the Standard & Poor's 500 Index and faster than the average for the whole sector, Bloomberg reported. The forecast came after first-quarter earnings of major health care stocks surpassed analysts' expectations.

The S&P Health Care Index has risen by 4.8% for the year to date, and 23.9% over the past calendar year.

Hedging costs rose to an eight-year high despite merger announcements from the biggest health care stocks in the wake of the biotech sell-off late in March, Bloomberg reported. Implied volatility has peaked its highest in eight years, propelled by gains from M&As from Pfizer (PFE), Allergan (AGN), Forest Laboratories (FRX) and Eli Lilly (LLY).

Stocks have skyrocketed by as much as 84% since 2011 due to the $285 billion proposed mergers and acquisitions, Bloomberg reported. The article noted investors were keen on hedging because of the recent health care stocks rally and to avoid a possible downdraft from  biotech, which suffered during the selloff.

The Nasdaq biotech index dipped by 20% late in March after peaking in February. Many analysts referred to the downdraft as a "bubble burst," while some analysts argue that a bubble is far from happening.

The S&P 500 Health Care Index has outpaced the S&P 500 by 32% in two years, with gains reaching a whopping 55%, according to the Wall Street Journal. The reason the sector grew this much was the $21.5 billion investors funneled into health care-focused mutual funds and exchange-traded funds since early last year.

Despite the recent slowdown, many health care stocks continue to provide investors protection.

Health care stocks seem to have the same key growth areas as the younger, smaller biotechs.

For instance, Johnson & Johnson's (JNJ) hepatitis C, immunology and oncology pipeline has boosted J&J's earnings, reported. Sales for its immunology drugs Simponi and Stelara rose by 9.3% and 31.8% to $715 million this year. The company's new Hep C drug, Olysio, also eclipsed expectations, with sales reaching $354 million. Sales for J&J's cancer drugs Velcade and Zytiga edged up by 15.8% (to $408 million) and 48.8% (to $512 million), respectively.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Crazy Weak U.S. Dollar Will Make These 10 Companies Huge Winners

Cramer: Goldman's Downgrade Of J&J Is 'Questionable'

Johnson & Johnson Stock Sinks, Goldman Downgrades to 'Sell'

The Best Companies for Women